Literature DB >> 2112979

A phase I-II trial of multimodality management of bulky gynecologic malignancy. Combined chemoradiosensitization and radiotherapy.

C R Kersh1, W C Constable, C A Spaulding, S S Hahn, W A Andersen, P T Taylor.   

Abstract

Between December 1983 and December 1987, there were 44 patients with bulky, nonresectable squamous cell carcinomas of the gynecologic tract (cervix, 36; vagina, eight) who were treated with concomitant chemotherapy and radiotherapy. Chemotherapy consisted of 5-fluorouracil (5-FU) 1g/m2 given by continuous intravenous infusion on days 1 through 4 and mitomycin C 10 mg/m2 given intravenously on day 1. External-beam irradiation was started on day 1 with a total calculated dose of 5000 cGy in 25 fractions employed. This was followed by brachytherapy. With a mean follow-up of 30.3 months and a median of 28 months, local control has been achieved in 32 of 44 patients (73%). The overall response rate was 88% (3-month partial response, 43%; 3-month complete response, 45%; 8-month partial response, 15%; 8-month complete response, 73%). Analysis of complications by Radiation Therapy Oncology Group (RTOG) criteria did not demonstrate an increase in acute or late complications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112979     DOI: 10.1002/1097-0142(19900701)66:1<30::aid-cncr2820660107>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Extracellular matrix components and proteolytic enzymes in uterine cervical carcinoma.

Authors:  V Bhuvarahamurthy; S Govindasamy
Journal:  Mol Cell Biochem       Date:  1995-03-09       Impact factor: 3.396

Review 2.  A Comprehensive Discussion in Vaginal Cancer Based on Mechanisms, Treatments, Risk Factors and Prevention.

Authors:  Sumit Kumar Baral; Partha Biswas; Md Abu Kaium; Md Aminul Islam; Dipta Dey; Md Al Saber; Tanjim Ishraq Rahaman; A M; Talha Bin Emran; Md Nazmul Hasan; Mi-Kyung Jeong; Ihn Han; Md Ataur Rahman; Bonglee Kim
Journal:  Front Oncol       Date:  2022-07-18       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.